These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 4028167)

  • 1. Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages.
    Lichtenstein A
    Cell Immunol; 1985 Sep; 94(2):521-35. PubMed ID: 4028167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.
    Lichtenstein A; Berek J
    Cancer Immunol Immunother; 1986; 22(1):24-30. PubMed ID: 3708631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
    Lichtenstein AK; Kahle J; Berek J; Zighelboim J
    J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
    Lichtenstein AK; Berek J; Kahle J; Zighelboim J
    Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for granulocyte-mediated macrophage activation after C. parvum immunization.
    Chapes SK; Haskill S
    Cell Immunol; 1983 Feb; 75(2):367-77. PubMed ID: 6831566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
    Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
    J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum.
    Lichtenstein A; Berek J; Bast R; Spina C; Hacker N; Knapp RC; Zighelboim J
    J Biol Response Mod; 1984 Aug; 3(4):371-8. PubMed ID: 6541243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect between neutrophils and Corynebacterium parvum in the process of macrophage activation.
    Chapes SK; Haskill S
    Cancer Res; 1984 Jan; 44(1):31-4. PubMed ID: 6228293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model.
    Berek JS; Cantrell JL; Lichtenstein AK; Hacker NF; Knox RM; Nieberg RK; Poth T; Elashoff RM; Lagasse LD; Zighelboim J
    Cancer Res; 1984 May; 44(5):1871-5. PubMed ID: 6713388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model.
    Knapp RC; Berkowitz RS
    Am J Obstet Gynecol; 1977 Aug; 128(7):782-6. PubMed ID: 560124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.
    Berek JS; Lichtenstein AK; Knox RM; Jung TS; Rose TP; Cantrell JL; Zighelboim J
    Cancer Res; 1985 Sep; 45(9):4215-8. PubMed ID: 4028011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Corynebacterium parvum in the activation of peritoneal macrophages. II. Identification of distinguishable anti-tumor activities by macrophage subpopulations.
    Chapes SK; Haskill S
    Cell Immunol; 1983 Feb; 76(1):49-57. PubMed ID: 6219754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
    Vanhaelen CP; Fisher RI
    Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of resistance to ectromelia virus infection by corynebacterium parvum in murine peritoneal macrophages.
    Cohen DA; Bubel HC
    J Reticuloendothel Soc; 1983 Jan; 33(1):35-46. PubMed ID: 6300395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella.
    Schafer R; Nacy CA; Eisenstein TK
    J Immunol; 1988 Mar; 140(5):1638-44. PubMed ID: 3279120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intracerebral administration of Corynebacterium parvum on the growth of brain tumors in mice.
    Kiya K; Toge T; Harada K; Uozumi T; Hattori T
    Gan; 1981 Jun; 72(3):446-50. PubMed ID: 7319201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
    Fisher B; Gebhardt M
    Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Corynebacterium parvum treatment and Toxoplasma gondii infection on macrophage-mediated cytostasis of tumour target cells.
    Krahenbuhl JL; Lambert LH; Remington JS
    Immunology; 1976 Dec; 31(6):837-46. PubMed ID: 992714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent macrophage stimulation by Corynebacterium parvum.
    Loose LD; Astry CL; Megirian R
    J Immunopharmacol; 1980; 2(3):349-65. PubMed ID: 6821558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.